CASI PHARMACEUTICALS, INC. Cost of Revenue
CASI PHARMACEUTICALS, INC. (CASIF) reported Cost of Revenue of $10.64 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-05-15
| Period end | Cost of Goods and Services Sold 12 month |
|---|---|
| 2025-12-31 | $10.64M 20-F · filed 2026-05-15 |
| 2024-12-31 | $17.39M 20-F · filed 2026-05-15 |
| 2023-12-31 | $13.83M 20-F · filed 2026-05-15 |
| 2022-12-31 | $15.83M 20-F · filed 2025-03-31 |
| 2021-12-31 | $12.56M 20-F · filed 2024-03-28 |
| 2020-12-31 | $9.51M 20-F · filed 2023-04-26 |